Welcome to our dedicated page for Revolution Medicines SEC filings (Ticker: RVMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Revolution Medicines, Inc. filings document a late-stage clinical oncology company focused on RAS-addicted cancers and RAS(ON) inhibitors. Its Form 8-K reports include financial results, clinical-program updates for daraxonrasib and other pipeline candidates, regulatory-related disclosures and material events tied to corporate progress.
The company’s SEC record also covers proxy governance, annual meeting matters, executive compensation, registered securities and capital-structure changes. Disclosures identify Nasdaq-listed common stock and warrants, and material-agreement filings describe convertible senior notes due 2033, related indenture terms and other financing arrangements used to support research and development, administrative expenses and potential commercialization activities.
Revolution Medicines, Inc. is offering $500,000,000 aggregate principal amount of 0.50% convertible senior notes due May 1, 2033. Interest accrues at 0.50% paid semi‑annually beginning November 1, 2026. The initial conversion rate is 5.0302 shares per $1,000 principal (= ~$198.80 per share). The company may settle conversions in cash, stock or a combination, and may redeem notes under specified stock‑price conditions on or after May 6, 2030. Concurrently, the company has a separate common stock offering of 10,563,381 shares, plus an underwriter option for up to 1,584,506 additional shares. Net proceeds to the company from the notes offering are estimated at approximately $486.8 million, to be used for general corporate purposes.
Morgan Stanley Smith Barney LLC filed a Form 144 notifying the sale of 120,000 shares of Common Stock by an affiliated seller, dated 04/15/2026. The filing lists an aggregate sale value of $17,641,200.00 and identifies NASDAQ as the market. The record also lists prior 10b5-1 sales in March 2026 including 30,000 and smaller lots.
Revolution Medicines is offering $750,000,000 of common stock, equal to 7,777,662 shares at an assumed public offering price of $96.43 per share. The prospectus supplement also describes a concurrent offering of $250,000,000 aggregate principal amount of convertible senior notes due 2033 (plus a $37,500,000 option).
The company reported 197,001,401 shares outstanding as of December 31, 2025. The shelf registration permits primary sales of common stock; the underwriters have a 30-day option to purchase up to $112,500,000 of additional shares. Completion of the equity offering is not contingent on the concurrent convertible note offering, and vice versa.
Revolution Medicines, Inc. is offering $250,000,000 aggregate principal amount of % convertible senior notes due 2033, with an underwriter option of up to $37,500,000. The notes pay semi‑annual interest, mature May 1, 2033 and are convertible into common stock based on an initial conversion rate and conversion price.
The offering is concurrent with a separate common stock offering of $750,000,000 (plus up to $112,500,000 option). No listing is planned for the notes; common stock trades on Nasdaq under RVMD and last reported sale price was $96.43 per share.
Revolution Medicines reported strong topline results from its global Phase 3 RASolute 302 trial of oral daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma. Daraxonrasib improved median overall survival to 13.2 months versus 6.7 months with standard intravenous chemotherapy, with a hazard ratio of 0.40 (p < 0.0001). The therapy also showed statistically significant, clinically meaningful gains in progression-free survival and was generally well tolerated, with a manageable safety profile and no new safety signals. Based on this first interim analysis, all progression-free and overall survival endpoints are considered final, and the company plans to submit these data to global regulators, including a future U.S. New Drug Application under a Commissioner’s National Priority Voucher.
The Vanguard Group filed Amendment No. 4 to a Schedule 13G/A reporting 0 shares (0%) of Revolution Medicines Inc common stock (CUSIP 76155X100). The filing states an internal realignment effective January 12, 2026 under SEC Release No. 34-39538 that disaggregated certain subsidiaries' holdings from The Vanguard Group, Inc. The Schedule lists the filing address as 100 Vanguard Blvd., Malvern, PA and is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
The filing declares no sole or shared voting or dispositive power over any Revolution Medicines shares and confirms ownership of 5% or less of the class.
Revolution Medicines, Inc. officer Anthony Mancini exercised options and sold shares of common stock. He exercised options for 37,450 shares of common stock at an exercise price of $33.6200 per share and received 37,450 shares.
On the same date, he sold a total of 37,450 shares in multiple open-market transactions at prices ranging from $93.2230 to $97.2071, pursuant to a Rule 10b5-1 trading plan adopted on December 24, 2025. After these transactions, he directly holds 54,800 shares of common stock, which the footnotes state includes 54,400 restricted stock units.
Revolution Medicines, Inc. officer Anthony Mancini filed an initial statement of beneficial ownership, detailing his existing equity position rather than reporting new trades. He directly holds 54,400 shares of Common Stock as Restricted Stock Units.
He also holds stock options over 149,800 shares of Common Stock at an exercise price of $33.62 per share, expiring on March 31, 2035. Twenty-five percent of these option shares vest on the first anniversary of the April 1, 2025 vesting commencement date, with the remainder vesting monthly over four years.
A separate stock option covers 26,200 shares of Common Stock at an exercise price of $102.02 per share, expiring on February 28, 2036. One forty-eighth of these shares vests on each monthly anniversary of the March 1, 2026 vesting commencement date, so they become fully vested after four years of continued service.
Revolution Medicines, Inc. Chief Development Officer Alan B. Sandler filed an initial beneficial ownership report. He directly holds 53,000 shares of Common Stock, which include 53,000 Restricted Stock Units. He also holds stock options over 167,300 shares at an exercise price of $58.84 per share expiring on October 31, 2035, and options over 11,700 shares at $102.02 per share expiring on February 28, 2036. These options vest monthly over four years starting from vesting commencement dates on November 1, 2025 and March 1, 2026, subject to his continued service.